HIV Treatment
IDWeek 2016: Omega-3 Fatty Acids May Improve Triglycerides and Inflammation in HIV+ People
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
Long-term use of omega-3 fatty acid supplements was associated with reduced levels of triglycerides and the inflammation biomarker C-reactive protein (CRP) in HIV-positive people with suppressed viral load, according to research presented last week at IDWeek 2016 in New Orleans.
Coverage of IDWeek 2016
- Details
- Category: HIV Treatment
- Published on Friday, 04 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans.
Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic resistance, and emerging infectious diseases such as Ebola virus and Zika virus.
Full listing of coverage by topic
11/4/16
IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women
- Details
- Category: Approved HIV Drugs
- Published on Monday, 31 October 2016 00:00
- Written by Liz Highleyman
A once-daily regimen containing the potent HIV integrase inhibitor dolutegravir worked better than an older atazanavir-containing regimen -- with higher rates of viral suppression both overall and across race subgroups -- in the ARIA trial, one of the few antiretroviral therapy studies to enroll only women, according to a presentation at IDWeek last week in New Orleans.
Coverage of HIV Drug Therapy Glasgow 2016
- Details
- Category: HIV Treatment
- Published on Friday, 04 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 International Congress on Drug Therapy in HIV Infection, held October 23-26, 2016, in Glasgow, Scotland.
Conference highlights include new antiretroviral therapies and strategies, HIV prevention, HIV-related comorbidities, and expanding access to treatment.
Full listing of coverage by topic
11/4/16
HIV Glasgow: Dolutegravir and Central Nervous System Side-Effects -- Abacavir, Older Age Increase the Risk
- Details
- Category: Approved HIV Drugs
- Published on Friday, 28 October 2016 00:00
- Written by Keith Alcorn
Insomnia, dizziness, headache, and other central nervous system (CNS) side effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to occur among women, people over age 60, and people starting abacavir at the same time, a German research group reported at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) this week.
More Articles...
- IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind
- HIV Glasgow: 2-Drug HIV Therapy Just as Effective as Standard 3-Drug Therapy
- HIVR4P 2016: More Viral Suppression Needed to Reduce HIV Infections Among Gay Men
- Researchers Observe Sustained Remission in Monkeys with HIV-Like Virus
Web Design and Development by